“With some investors now looking to take on a bit more risk, they are turning to the ultimate risk/reward plays: biotech stocks,” notes the author of today’s article. One of the few major catalysts for biotech stocks is regulatory approval – and the author highlights “three compelling biotech stocks with upcoming Prescription Drug User Fee Act (PDUFA) dates, the deadline by which the FDA must decide to approve or reject a new application.” For these three biotech stocks with “Strong Buy” analyst ratings and significant upside potential – including one firm at the forefront of women’s reproductive health – CLICK HERE.
